Home Cart Sign in  
Chemical Structure| 835598-94-2 Chemical Structure| 835598-94-2

Structure of GLX351322
CAS No.: 835598-94-2

Chemical Structure| 835598-94-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4) that inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GLX351322

CAS No. :835598-94-2
Formula : C21H25N3O5S
M.W : 431.51
SMILES Code : O=C(C1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)SC4=C1CCC4)OCC
MDL No. :MFCD05123600
InChI Key :KEVHLTCEMHIJTQ-UHFFFAOYSA-N
Pubchem ID :2697686

Safety of GLX351322

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
fibroblast-like synoviocytes 20 μM 1 h To analyze the effect of NOX4 inhibition on cell migration induced by cytokines. PMC7227051
Primary cortical neurons 10 µM 2 hours GLX351322 increased cell viability in Aβ1–42-treated neurons PMC7791017
Primary cortical neurons 10 μM 24 hours GLX351322 increased the cell viability in Aβ1–42-treated neurons PMC7791017
BCPAP cells 5 μM 48 hours GLX351322 significantly reduced cell viability under starvation independent of lenvatinib, suggesting its mechanism is different from Lenvatinib. PMC8990679
TPC-1 cells 5 μM 48 hours GLX351322 significantly reduced cell viability under starvation independent of lenvatinib, suggesting its mechanism is different from Lenvatinib. PMC8990679
LRBCs 5 μM 48 hours GLX351322 significantly decreased the survival ratios in lenvatinib-treated LRBCs cells independent of starvation, indicating that the combinatory usage of lenvatinib and GLX351322 can maximize the inhibitory effect. PMC8990679

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice APPswe/PS1dE9 (APP/PS1) transgenic mice Intraperitoneal injection 5 mg/kg/day Once daily for 4 weeks GLX351322 treatment ameliorated synaptic and memory functions, reduced oxidative stress and amyloid levels in APP/PS1 mice PMC7791017
Mice APP/PS1 transgenic mice Intraperitoneal injection 5 mg/kg/day Once daily for 4 weeks GLX351322 improved synaptic and memory functions, and reduced oxidative stress and amyloid levels in APP/PS1 mice PMC7791017
C57Bl/6J mice Intracranial xenograft model Oral 3.8 mg/day/kg Once daily for 2 weeks GLX351322 inhibited NOX4 expression, reduced ROS production and angiogenesis, and suppressed tumor growth. PMC9585329
NOD/SCID mice BCPAP cells or LRBCs cells xenograft model Oral GLX351322 (5 mg/kg), Lenvatinib (30 mg/kg) once every 3 days for 70 days The combination of GLX351322 and Lenvatinib completely suppressed the growth of BCPAP and LRBCs-derived tumors, significantly improving the survival rate of mice. PMC8990679

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.17mL

4.63mL

2.32mL

References

 

Historical Records

Categories